Medistim ASA reports strong Q3 2025 growth, record year-to-date sales

Medistim ASA announced a strong third quarter for 2025, with sales revenues growing 25.7% to MNOK 166.8, contributing to a record year-to-date sales revenue of MNOK 517.5, up 25.8%. Operating profit (EBIT) increased by 27.1% to MNOK 40.6 for the quarter, yielding a 24.3% EBIT margin. Year-to-date, EBIT surged by 46.2% to MNOK 153.9, with a 29.7% EBIT margin. Currency-neutral sales of own products rose by 29.8% for the quarter and 28.0% year-to-date.

Geographically, americas and APAC regions showed robust currency-neutral growth of 35.7% and 194% respectively for the quarter, while EMEA sales declined by 11.8%. Total flow and imaging procedures sold in the USA increased by 70.4% in Q3 2025 compared to the prior year, reaching 35,072 procedures. Medistim maintains a solid cash position of MNOK 157.6 at quarter-end, even after paying a dividend of NOK 6.00 per share (total MNOK 109.5) in May, with no interest-bearing bank loans. The company also introduced the new MiraQ INTUI™ software platform in Q3 2025, which is expected to drive further growth.